Literature DB >> 20952217

The VIRTUE Registry of type B thoracic dissections--study design and early results.

.   

Abstract

INTRODUCTION: Endovascular procedures for repair of Type B aortic dissection have become increasingly common and are often considered to be first line therapy for acute complicated dissections. The long term durability of these repairs is largely undefined.
METHODS: The Virtue Registry is a prospective, non-randomised, multi centre European Clinical Registry designed to inform on the clinical and morphological outcomes of 100 patients with Type B aortic dissection treated with the Medtronic Valiant thoracic stent graft. Patients with acute, sub-acute and chronic Type B dissections will be prospectively followed for three years. Clinical outcomes and aortic morphology will be defined.
RESULTS: Fifty patients had an acute dissection, 24 a sub-acute dissection and 26 a chronic lesion. The 30-day mortality for the acute, sub-acute and chronic lesions was 8%, 0% and 0%. The in hospital composite outcome (mortality, stroke or paraplegia) for the three groups was 16%, 0% and 3.8% respectively. The effect of left subclavian artery (LSCA) revascularisation was defined with the composite endpoint of patients with a covered, non-revascularised LSCA being 20% as compared to 5.8% in the covered, revascularised group.
CONCLUSION: The early outcomes for the treatment of Type B aortic dissection are reported in the Virtue Registry. Longer term follow-up is planned to report on clinical and morphological outcomes up to 36 months post-procedure.
Copyright © 2010. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 20952217     DOI: 10.1016/j.ejvs.2010.08.016

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  8 in total

1.  Management of aortic dissection: medical therapy and intervention. Is there a growing role for endovascular techniques?

Authors:  Kristine C Orion; James H Black
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-06

Review 2.  Indications for Thoracic EndoVascular Aortic Repair (TEVAR): A Brief Review.

Authors:  Frank Manetta; Joshua Newman; Allan Mattia
Journal:  Int J Angiol       Date:  2018-08-02

Review 3.  Management of complicated and uncomplicated acute type B dissection. A systematic review and meta-analysis.

Authors:  Konstantinos G Moulakakis; Spyridon N Mylonas; Ilias Dalainas; John Kakisis; Thomas Kotsis; Christos D Liapis
Journal:  Ann Cardiothorac Surg       Date:  2014-05

4.  Endovascular repair of acute complicated type B aortic dissection-systematic review and meta-analysis of long-term survival and reintervention.

Authors:  Ashley R Wilson-Smith; Benjamin Muston; Harish Kamalanathan; Amanda Yung; Cheng-Hao Jacky Chen; Prachi Sahai; Aditya Eranki
Journal:  Ann Cardiothorac Surg       Date:  2021-11

5.  Five-Year Results of Aortic Remodeling for Acute, Subacute, and Chronic Type B Aortic Dissection Following Endovascular Repair.

Authors:  Guangmin Yang; Hongwei Ge; Guangyan Wu; Yepeng Zhang; Leiyang Zhang; Ming Zhang; Xiaoqiang Li; Min Zhou
Journal:  Front Cardiovasc Med       Date:  2022-05-17

6.  Endovascular management of chronic post-dissection aneurysms.

Authors:  Kyriakos Oikonomou; Athanasios Katsargyris; Wolfgang Ritter; Domenico Spinelli; Yuki Seto; Eric L Verhoeven
Journal:  Ann Cardiothorac Surg       Date:  2014-05

7.  Risk factors of distal segment aortic enlargement after complicated type B aortic dissection.

Authors:  Yu Shen; Simeng Zhang; Guanglang Zhu; Yanqing Chen; Zheng Chen; Zaiping Jing; Qingsheng Lu
Journal:  J Interv Med       Date:  2019-10-23

8.  Outcomes of Patients With Acute Type B (DeBakey III) Aortic Dissection: A 13-Year, Single-Center Experience.

Authors:  Rana O Afifi; Harleen K Sandhu; Samuel S Leake; Mina L Boutrous; Varsha Kumar; Ali Azizzadeh; Kristofer M Charlton-Ouw; Naveed U Saqib; Tom C Nguyen; Charles C Miller; Hazim J Safi; Anthony L Estrera
Journal:  Circulation       Date:  2015-08-25       Impact factor: 29.690

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.